166 related articles for article (PubMed ID: 11038761)
1. [Immunohistochemical study on the expression of c-erbB2 oncoprotein in breast tumors].
Zhang Z; Xu G; Liu S
Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):287-9. PubMed ID: 11038761
[TBL] [Abstract][Full Text] [Related]
2. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
Yang JQ; Chen L; Xing TY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828
[TBL] [Abstract][Full Text] [Related]
3. [Expression of c-erbB2 protein and its relation to prognosis in 284 primary breast cancer patients].
Yang LF; Song ST; Li XB; Jiang ZF; Liu XQ; Ma WN; Jiao XP; Guo SQ
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):294-7. PubMed ID: 16875632
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of c-erbB2 expression in breast cancer.
Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S
J Surg Oncol; 2002 Apr; 79(4):216-23. PubMed ID: 11920778
[TBL] [Abstract][Full Text] [Related]
5. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
6. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
8. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein.
Looi LM; Cheah PL
Malays J Pathol; 1998 Jun; 20(1):19-23. PubMed ID: 10879259
[TBL] [Abstract][Full Text] [Related]
9. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study.
Ko SS; Na YS; Yoon CS; Park JY; Kim HS; Hur MH; Lee HK; Chun YK; Kang SS; Park BW; Lee JH
Int J Surg Pathol; 2007 Apr; 15(2):98-109. PubMed ID: 17478762
[TBL] [Abstract][Full Text] [Related]
10. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
11. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological and biological features of breast cancer in young females and their relationship with prognosis].
Meng J; Lang RG; Fan Y; Fu L
Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):284-8. PubMed ID: 17760256
[TBL] [Abstract][Full Text] [Related]
13. Correlation between histological grade and c-erbB2 oncoprotein overexpression in infiltrating ductal carcinoma of breast.
Looi LM; Cheah PL; Yap SF
Malays J Pathol; 1997 Jun; 19(1):35-9. PubMed ID: 10879240
[TBL] [Abstract][Full Text] [Related]
14. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
Aryandono T; Harijadi ; Ghozali A
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
17. c-erbB-2, p53 protein expression and steroid hormone receptors in breast carcinomas: an immunohistochemical study.
Yokota T; Imamura M; Teshima S; Suzuki H; Tezuka F; Kikuchi S; Kunii Y; Yamauchi H
Anticancer Res; 1999; 19(5B):4007-12. PubMed ID: 10628345
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic significance of expression of c-ERBB-2 oncoprotein in breast cancer patients].
Osaki A; Toi M; Yamada H; Kawami H; Kuroi K; Toge T
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1181-5. PubMed ID: 1675844
[TBL] [Abstract][Full Text] [Related]
19. [Immunohistochemical analysis of p53 and c-erbB-2 in breast cancer].
Castiglioni T; Elsner B; Curutchet HP; Montesinos M; Debonis D
Medicina (B Aires); 1995; 55(5 Pt 1):415-20. PubMed ID: 8728771
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneic expression of estrogen receptor between the primary tumor and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome.
Iguchi C; Nio Y; Itakura M
J Surg Oncol; 2003 Jun; 83(2):85-93. PubMed ID: 12772201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
